Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer

Not Applicable

• Conditions: advanced non-small cell lung cancer

• Registration Number: JPRN-UMIN000007873
• Lead Sponsor: Shiga University of Medical Science Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-01
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1.Other malignancy requiring treatment 2.Concurrent treatment with anticancer drug, steroids, immunosuppressing agent, radiation, immunotherapy, hyperthermia, or surgery. 3.Active and uncontrolled infectious disease 4.Active and uncontrolled hepatic dysfunction, kidney dysfunction, cardiac disease, or lung disease (i.e. interstitial pneumonia). 5.Autoimmune disease. 6.HIV-Ab or antigen positive 7.Prior anti-cancer therapy within 4 weeks 8.Laboratory values as follows: 2000<mm3 < WBC < 15000/mm3, Platelet count < 50000/mm3, Asparate transaminase > 5 X cutoff value, Alanine transaminase > 5 X cutoff value, Total bilirubin > 3 X cutoff value, and Serum creatinine > 3X cutoff value. 9.Patients knows HLA-A type. 10.Breastfeeding and Pregnancy (woman of child bearing potential) 11.Refusal of pregnancy conception. 12.Treated with S-488401, S-488402, or S-488403. 13.Treated with other investigational drug within 3 months prior to receiving S-48810 treatment. 14.Decision of nonenrollment of the patients by principal investigator or physician-in-charge from the view point of patient's safety.

Study & Design

• Study Type: Interventional
• Study Design: Not specified